Cresco Labs Launches Flagship Flower Brand in Germany

Article content

New market entry pilots three signature Cresco offerings

Article content

/Germany/EU Regulatory Notice: This communication is not intended for patients or the general public in Germany or the EU and does not constitute advertising for prescription-only medicinal products. Any product-specific information will be provided exclusively to healthcare professionals through appropriate channels in accordance with applicable law./

Article content

Article content

CHICAGO — Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today announced the launch of Cresco-branded flower in Germany, marking the Company’s first commercial entry into the European Union. The launch reflects Cresco’s expanded growth strategy as it pilots new investment platforms beyond U.S. cannabis.

Article content

Article content

Germany is one of the world’s fastest-growing regulated cannabis markets, supported by a well-structured regulatory framework and an expanding patient base. The launch serves as an opportunity to gather insights while building a foundation for Cresco Labs’ future expansion potential in international markets.

Article content

Article content

“After extensive work understanding the European landscape, we’re confident that Cresco can deliver meaningful value through our portfolio of market leading brands, proven operational capabilities, and deep experience operating in dynamic regulatory environments,” said Charlie Bachtell, CEO of Cresco Labs. “Our objective is to use these insights to guide future growth decisions in evolving markets.”

Article content

Cresco Labs is partnering with Blossom, the Company’s EU GMP-certified manufacturing partner in Portugal, to introduce three signature flower products, each aligned with specific patient effects.

Article content

Cresco products are now available via prescription through licensed pharmacies across Germany.

Article content

About Cresco Labs Inc.

Article content

Cresco Labs’ mission is to normalize and professionalize the cannabis industry through a CPG approach to building national brands and a customer-focused retail experience, while acting as a steward for the industry on legislative and regulatory-focused initiatives. As a leader in cultivation, production, and branded product distribution, the Company is leveraging its scale and agility to grow its portfolio of brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s, and Remedi, on a national level. The Company also operates highly productive dispensaries nationally under the Sunnyside brand that focus on building patient and consumer trust and delivering ongoing education and convenience in a wonderfully traditional retail experience. Through year-round policy, community outreach and SEED initiative efforts, Cresco Labs embraces the responsibility to support communities through authentic engagement, economic opportunity, investment, workforce development, and legislative initiatives designed to create the most responsible, respectable and robust cannabis industry possible. Learn more about Cresco Labs’ journey by visiting www.crescolabs.com or following the Company on Facebook, X or LinkedIn.

Article content

Forward-Looking Statements

Article content

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking statements”). Such forward-looking statements are not representative of historical facts or information or current condition but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential,’ or ‘continue,’ or the negative of those forms or other comparable terms. The Company’s forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the Company’s Annual Information Form for the year ended December 31, 2024, filed on SEDAR+ and EDGAR, other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs’ shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event, or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.

Article content

Article content

Article content

Article content

View source version on businesswire.com:

Article content

Article content

Article content

Contacts

Article content

Media

Article content

Article content

Article content

Investors

Article content

Article content

TJ Cole, Cresco Labs

Article content

Article content

SVP, Corporate Development & Investor Relations

Article content

Article content

Article content

For general Cresco Labs inquiries:

Article content

Article content

312-929-0993

Article content

Article content

Article content

Article content